<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01928446</url>
  </required_header>
  <id_info>
    <org_study_id>590</org_study_id>
    <nct_id>NCT01928446</nct_id>
  </id_info>
  <brief_title>Lithium for Suicidal Behavior in Mood Disorders</brief_title>
  <acronym>Li+</acronym>
  <official_title>CSP #590 - Lithium for Suicidal Behavior in Mood Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational evidence and findings from clinical trials conducted for other reasons suggest&#xD;
      that lithium, a drug used for the treatment of bipolar disorder, and, to a lesser extent,&#xD;
      depression, may reduce rates of suicides and suicide attempts. However, this hypothesis has&#xD;
      not yet been adequately examined in a randomized clinical trial conducted specifically to&#xD;
      test lithium's efficacy in preventing suicides. This clinical trial fills this gap.&#xD;
&#xD;
      This study is feasible within the Department of Veterans Affairs (VA) because it is a large,&#xD;
      integrated health system with existing programs for identifying patients at risk for suicide&#xD;
      and delivering enhanced services. In VA, approximately 12,000 patients with depression or&#xD;
      bipolar disorder survive a suicide attempt or related behavior each year, and 15% of them&#xD;
      repeat within one year. Experimental treatment in this study will supplement usual care for&#xD;
      major depression or bipolar disorder, as well as VA's standard, enhanced management for&#xD;
      patients at high risk.&#xD;
&#xD;
      The investigators will recruit 1862 study participants, from approximately 30 VA Hospitals.&#xD;
      Participants will be patients with bipolar disorder or depression who have survived a recent&#xD;
      episode of suicidal self-directed violence or were hospitalized specifically to prevent&#xD;
      suicide. Randomly, half will receive lithium, and half will receive placebo. Neither the&#xD;
      patients nor their doctors will know whether a particular person has received lithium or&#xD;
      placebo. The treatment will be administered and the patients will be followed for one year,&#xD;
      after which patients will go back to usual care. Recruitment will occur over 3 years.&#xD;
&#xD;
      The investigators are primarily interested in whether lithium leads to increases in the time&#xD;
      to the first repeated episode of suicidal behavior, including suicide attempts, interrupted&#xD;
      attempts, hospitalizations specifically to prevent suicide, and deaths from suicide. In&#xD;
      addition, this study will allow us to explore whether lithium decreases the total number of&#xD;
      suicidal behaviors, and whether it has comparable effects on impulsive and non-impulsive&#xD;
      behaviors. If there is an effect of lithium, the investigators will be interested in whether&#xD;
      or not it could be attributed to improved control of the underlying mental health condition,&#xD;
      or, alternatively, whether it represents a direct effect of suicide-related behavior.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: To test the hypothesis that lithium augmentation of enhanced usual care will&#xD;
      reduce the rate of repeated episodes of suicidal self-directed violence (repeated suicide&#xD;
      attempts, interrupted attempts, hospitalizations specifically to prevent suicide, and deaths&#xD;
      from suicide) in participants with bipolar disorder or depression who have survived a recent&#xD;
      event.&#xD;
&#xD;
      Background: The hypothesis that lithium can prevent suicide in patients with bipolar disorder&#xD;
      and depression is based on data from observational studies and randomized clinical trials&#xD;
      conducted to evaluate other outcomes. The question about the effectiveness of lithium for&#xD;
      suicide prevention is one of major scientific, clinical, and public health significance.&#xD;
      There have been no adequately powered clinical trials conducted specifically to evaluate&#xD;
      suicide behaviors as an outcome. Two recent randomized clinical trials failed to recruit&#xD;
      adequate numbers of subjects to be conclusive.&#xD;
&#xD;
      The VHA, as a large national healthcare system with an established program for identifying&#xD;
      new suicide attempts, evaluating patients for underlying mental health and medical&#xD;
      conditions, providing needed services, connecting Veterans to state-of-the-art suicide risk&#xD;
      management, and monitoring outcomes is uniquely able to conduct a large scale clinical trial&#xD;
      of lithium for suicide prevention.&#xD;
&#xD;
      The rationale for the study is based on the following:&#xD;
&#xD;
        -  Data from observational studies and double-blind randomized clinical trials suggest that&#xD;
           lithium can prevent suicide-related behaviors in patients with bipolar disorder and&#xD;
           major depression.&#xD;
&#xD;
        -  The high risk of suicide in Veterans receiving health care services from VHA has&#xD;
           persisted despite extensive improvements in mental health services and in programs for&#xD;
           suicide prevention.&#xD;
&#xD;
        -  Each month, there are over 1,100 unique VHA patients with bipolar disorder or depression&#xD;
           who attempt suicide and survive.&#xD;
&#xD;
        -  Surviving a suicide attempt is the most powerful known risk factor for death from&#xD;
           suicide in VA and elsewhere.&#xD;
&#xD;
        -  Approximately 15% of VA survivors reattempt or die from suicide within one year.&#xD;
&#xD;
        -  Evaluating rates of reattempts in those who have survived attempts is an established and&#xD;
           effective method for testing interventions that may prevent suicide.&#xD;
&#xD;
        -  Experimental treatment in CSP-590 would supplement usual care for major depression or&#xD;
           bipolar disorder.&#xD;
&#xD;
        -  Study procedures for the management of suicide risk would meet or exceed VA standards&#xD;
           and requirements.&#xD;
&#xD;
        -  Study procedures optimize the safety of lithium, including the potential risk of&#xD;
           overdoses, and meet or exceed all published practice standards. The trial will utilize&#xD;
           multiple strategies to minimize risks including frequent monitoring and assessment,&#xD;
           determination of lithium levels during titration and at steady state, and dispensing&#xD;
           medications in limited quantities in blister packs.&#xD;
&#xD;
        -  The investigator's survey of VA psychiatrists indicates that the question is clinically&#xD;
           important and compelling and that a clinical trial that demonstrated the hypothesized&#xD;
           effect would transform the clinical management of suicidality.&#xD;
&#xD;
      Design: Randomized, double-blind, placebo-controlled clinical trial of lithium versus placebo&#xD;
      augmentation of enhanced usual care.&#xD;
&#xD;
      Patient population: VHA patients with bipolar disorder or depression who have survived a&#xD;
      recent episode of suicidal self-directed violence.&#xD;
&#xD;
      Primary outcome: Time to the first repeated episode of suicidal self-directed violence,&#xD;
      including suicide attempts, interrupted attempts, hospitalizations specifically to prevent&#xD;
      suicide, and deaths from suicide&#xD;
&#xD;
      Duration: Total study duration will be 4.5 years. Recruitment will occur over 3 years.&#xD;
      Participants will be followed for one year.&#xD;
&#xD;
      Sample size calculations and number of sites required: The design of the study is based on&#xD;
      testing for a 37% reduction in the rate of repeated suicidal self-directed violence, a figure&#xD;
      based on an effect size of approximately 43% observed in recent studies and then allowing for&#xD;
      attenuation due to non-adherence. Adjusting for potential data loss due to attrition, 90%&#xD;
      statistical power to detect a significant 37% reduction in reattempt rates at 5% overall type&#xD;
      I error would require 1862 subjects. With recruitment of 20% of eligible subjects over a&#xD;
      three year period, this would require approximately 9310 potentially eligible subjects. Based&#xD;
      on current suicide surveillance data, this could be achieved with 29 sites.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    terminated early due to non-safety related DMC recommendations&#xD;
  </why_stopped>
  <start_date type="Actual">July 8, 2015</start_date>
  <completion_date type="Actual">December 19, 2019</completion_date>
  <primary_completion_date type="Actual">December 19, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Event Hazard Rate. Event is a First Repeated Episode of Suicide Related Event, Including Suicide Attempts, Interrupted Attempts and Hospitalizations for Prevention of Attempts.</measure>
    <time_frame>1 year</time_frame>
    <description>The primary hypothesis tested is that lithium augmentation of enhanced usual care is superior to enhanced usual care plus placebo for the prevention of repeated episodes of suicidal self-directed violence over time. The investigators posit a one-year repeat rate of 15% in the placebo group and a 37% reduction of events in the intervention group.&#xD;
Suicidal self-directed violence includes non-fatal suicide attempts, interrupted attempts (attempts interrupted by patient or by others), hospitalization to prevent suicide and deaths from suicide.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Compliant Participants With Episode of Self-directed Violence (Per Protocol Analyses)</measure>
    <time_frame>1 year</time_frame>
    <description>Compliance is defined as taking 80% or more of study medication over the entire clinical trial.&#xD;
Episode of self-directed violence is defined as: First Repeated Episode of Suicide Related Event, Including Suicide Attempts, Interrupted Attempts, Hospitalization to Prevent Suicide and death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Subtypes of Suicidal Self-directed Violence for All Recurring Events</measure>
    <time_frame>1 year</time_frame>
    <description>Subtypes of suicidal self-directed violence:&#xD;
Self-directed violence;&#xD;
Interrupted self-directed violence;&#xD;
Hospitalization to prevent suicide;&#xD;
Death from suicide - there were too few deaths in the study, making data insufficient to perform analysis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">519</enrollment>
  <condition>Depressive Disorder</condition>
  <condition>Bipolar Disorder</condition>
  <condition>Suicide</condition>
  <condition>Suicide, Attempted</condition>
  <arm_group>
    <arm_group_label>Lithium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lithium in the form of extended release lithium carbonate. Subjects will be started on 600 mg/day (300mg bid) until steady state at target plasma levels between 0.6 and 0.8 meq/liter is achieved. The lowest dose will be 300 mg/day. Lithium will be prescribed for the duration of follow-up (1 year).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets will be given to the subjects for the duration of follow-up (1 year). Dose adjustments will mimic the intervention arm of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lithium</intervention_name>
    <description>Lithium in the form of extended release lithium carbonate. Subjects will be started on 600 mg/day (300mg bid) until steady state at target plasma levels between 0.6 and 0.8 meq/liter is achieved. The lowest dose will be 300 mg/day. Lithium will be prescribed for the duration of follow-up (1 year).</description>
    <arm_group_label>Lithium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral placebo tablets will be administered for the duration of follow-up (1 year).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be a Veteran of the United States Armed Forces&#xD;
&#xD;
          -  Survived an episode of suicidal self-directed violence (including suicide attempts and&#xD;
             interrupted attempts) that occurred within six months of admission to the study, or&#xD;
             they were admitted within the past six months to a mental health inpatient unit&#xD;
             specifically to prevent suicide&#xD;
&#xD;
          -  Have a diagnosis of an affective disorder meeting DSM-IV-TR (2000) criteria for&#xD;
             Bipolar I Disorder, Bipolar II Disorder, or current or recurrent Major Depressive&#xD;
             Disorder&#xD;
&#xD;
          -  Are able and willing to identify one or more family members, friends, or other&#xD;
             contacts and give permission for both clinical providers and the Research Team to&#xD;
             contact them if the patient cannot be reached&#xD;
&#xD;
          -  Are able to provide informed consent&#xD;
&#xD;
          -  There is concurrence from the patient's mental health provider about&#xD;
             inclusion/exclusion criteria and confirmation of the providers' willingness to work&#xD;
             with the research team in managing the patient during the course of the study. The&#xD;
             provider responsible for the patient's general medical care has been made aware of the&#xD;
             participation&#xD;
&#xD;
          -  Must be registered at a VA Medical Center&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Schizophrenia or schizoaffective disorder&#xD;
&#xD;
          -  Cognitive impairment defined as a Brief Orientation Memory and Concentration Test&#xD;
             score &gt; 10&#xD;
&#xD;
          -  Lack of decision-making capacity to evaluate the risks versus the benefits of&#xD;
             participation as determined by Jeste's brief instrument for assessing decisional&#xD;
             capacity, or adjudication of incompetence and the appointment of a guardian or&#xD;
             conservator&#xD;
&#xD;
          -  Six or more previous lifetime suicide attempts as ascertained through SPAN, reports&#xD;
             from family, or patient self-report&#xD;
&#xD;
          -  Current or recent (within six months) use of lithium&#xD;
&#xD;
          -  History of significant adverse effects of lithium as ascertained through the medical&#xD;
             record or self-report&#xD;
&#xD;
          -  Unstable medical conditions or specific medical comorbidity:&#xD;
&#xD;
               -  Congestive heart failure by Framingham criteria&#xD;
&#xD;
               -  QTc greater than or equal to 450 ms for men and greater than or equal to 460 ms&#xD;
                  for women&#xD;
&#xD;
               -  Chronic renal failure defined by national Kidney Foundation Disease Outcome&#xD;
                  Quality Initiative (KDOQI) criteria&#xD;
&#xD;
          -  Any possibility of being pregnant or not on appropriate birth control&#xD;
&#xD;
          -  Lactation and breastfeeding&#xD;
&#xD;
          -  Concurrent medications:&#xD;
&#xD;
               -  All diuretics except amiloride&#xD;
&#xD;
               -  Haloperidol&#xD;
&#xD;
               -  Clozapine&#xD;
&#xD;
          -  Active substance abuse:&#xD;
&#xD;
               -  Active alcohol or opiate dependence requiring medically supervised withdrawal and&#xD;
                  stabilization&#xD;
&#xD;
               -  Active cocaine, methamphetamine, other stimulant, hallucinogen, or cannabis abuse&#xD;
                  requiring stabilization&#xD;
&#xD;
          -  Enrollment in another randomized interventional clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ira R Katz, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phoenix VA Health Care System, Phoenix, AZ</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Arizona VA Health Care System, Tucson, AZ</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Arkansas Veterans Healthcare System Eugene J. Towbin Healthcare Center, Little Rock, AR</name>
      <address>
        <city>North Little Rock</city>
        <state>Arkansas</state>
        <zip>72114-1706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Loma Linda Healthcare System, Loma Linda, CA</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92357</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Palo Alto Health Care System, Palo Alto, CA</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304-1290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA San Diego Healthcare System, San Diego, CA</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Eastern Colorado Health Care System, Denver, CO</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami VA Healthcare System, Miami, FL</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando VA Medical Center, Orlando, FL</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta VA Medical and Rehab Center, Decatur, GA</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edward Hines Jr. VA Hospital, Hines, IL</name>
      <address>
        <city>Hines</city>
        <state>Illinois</state>
        <zip>60141-5000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richard L. Roudebush VA Medical Center, Indianapolis, IN</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-2884</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis VA Health Care System, Minneapolis, MN</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Southern Nevada Healthcare System, North Las Vegas, NV</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Sierra Nevada Health Care System, Reno, NV</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asheville VA Medical Center, Asheville, NC</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louis Stokes VA Medical Center, Cleveland, OH</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Portland Health Care System, Portland, OR</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michael E. DeBakey VA Medical Center, Houston, TX</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Veterans Health Care System, Temple, TX</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Salt Lake City Health Care System, Salt Lake City, UT</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System Seattle Division, Seattle, WA</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William S. Middleton Memorial Veterans Hospital, Madison, WI</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clement J. Zablocki VA Medical Center, Milwaukee, WI</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53295-1000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 15, 2013</study_first_submitted>
  <study_first_submitted_qc>August 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2013</study_first_posted>
  <results_first_submitted>March 23, 2021</results_first_submitted>
  <results_first_submitted_qc>June 2, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 24, 2021</results_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lithium</keyword>
  <keyword>Placebo</keyword>
  <keyword>Double-blind methods</keyword>
  <keyword>Clinical Trials, Randomized</keyword>
  <keyword>Veterans</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Suicide</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
    <mesh_term>Suicide, Attempted</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lithium Carbonate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual Participant Data will be made available after study closure only to research credentialed Veterans Affairs researchers who submit a valid study question to their IRB of record. A Data Use Agreement will be in effect between the researcher and the coordinating center</ipd_description>
    <ipd_time_frame>After primary and secondary analyses and subsequent publications</ipd_time_frame>
    <ipd_access_criteria>Executed data use agreement with CSP Coordinating Center approval</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 3, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT01928446/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 1, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT01928446/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: Screening ICF</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT01928446/ICF_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: Randomization ICF</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT01928446/ICF_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Assessed for eligibility (n=21887).&#xD;
Signed 1st consent (n=722);&#xD;
Excluded: did not meet inclusion criteria (n= 173).&#xD;
Signed 2nd consent (n=599);&#xD;
Excluded:&#xD;
not randomized (n=78);&#xD;
assigned to treatment arm, but dropped out prior to receiving Study Meds (n=2).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lithium</title>
          <description>Lithium in the form of extended release lithium carbonate. Subjects will be started on 600 mg/day (300mg bid) until steady state at target plasma levels between 0.6 and 0.8 meq/liter is achieved. The lowest dose will be 300 mg/day. Lithium will be prescribed for the duration of follow-up (1 year).</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo tablets will be given to the subjects for the duration of follow-up (1 year). Dose adjustments will mimic the intervention arm of the study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="255"/>
                <participants group_id="P2" count="264"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="144">39 subjects stopped study drug but continued with followup</participants>
                <participants group_id="P2" count="125">23 subjects stopped study drug but continued with followup</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="139"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lithium</title>
          <description>Lithium in the form of extended release lithium carbonate. Subjects will be started on 600 mg/day (300mg bid) until steady state at target plasma levels between 0.6 and 0.8 meq/liter is achieved. The lowest dose will be 300 mg/day. Lithium will be prescribed for the duration of follow-up (1 year).</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo tablets will be given to the subjects for the duration of follow-up (1 year). Dose adjustments will mimic the intervention arm of the study</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="255"/>
            <count group_id="B2" value="264"/>
            <count group_id="B3" value="519"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.2" spread="12.4"/>
                    <measurement group_id="B2" value="42.4" spread="12.4"/>
                    <measurement group_id="B3" value="42.8" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="212"/>
                    <measurement group_id="B2" value="225"/>
                    <measurement group_id="B3" value="437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="220"/>
                    <measurement group_id="B2" value="217"/>
                    <measurement group_id="B3" value="437"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="185"/>
                    <measurement group_id="B2" value="192"/>
                    <measurement group_id="B3" value="377"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Event Hazard Rate. Event is a First Repeated Episode of Suicide Related Event, Including Suicide Attempts, Interrupted Attempts and Hospitalizations for Prevention of Attempts.</title>
        <description>The primary hypothesis tested is that lithium augmentation of enhanced usual care is superior to enhanced usual care plus placebo for the prevention of repeated episodes of suicidal self-directed violence over time. The investigators posit a one-year repeat rate of 15% in the placebo group and a 37% reduction of events in the intervention group.&#xD;
Suicidal self-directed violence includes non-fatal suicide attempts, interrupted attempts (attempts interrupted by patient or by others), hospitalization to prevent suicide and deaths from suicide.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lithium</title>
            <description>Lithium in the form of extended release lithium carbonate. Subjects will be started on 600 mg/day (300mg bid) until steady state at target plasma levels between 0.6 and 0.8 meq/liter is achieved. The lowest dose will be 300 mg/day. Lithium will be prescribed for the duration of follow-up (1 year).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets will be given to the subjects for the duration of follow-up (1 year). Dose adjustments will mimic the intervention arm of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Event Hazard Rate. Event is a First Repeated Episode of Suicide Related Event, Including Suicide Attempts, Interrupted Attempts and Hospitalizations for Prevention of Attempts.</title>
          <description>The primary hypothesis tested is that lithium augmentation of enhanced usual care is superior to enhanced usual care plus placebo for the prevention of repeated episodes of suicidal self-directed violence over time. The investigators posit a one-year repeat rate of 15% in the placebo group and a 37% reduction of events in the intervention group.&#xD;
Suicidal self-directed violence includes non-fatal suicide attempts, interrupted attempts (attempts interrupted by patient or by others), hospitalization to prevent suicide and deaths from suicide.</description>
          <units>Monthly Hazard rate</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0382"/>
                    <measurement group_id="O2" value="0.0348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Model1 - Treatment only: unadjusted for other covariates</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.61</p_value>
            <method>Log Rank</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Model2 - Treatment only: unadjusted with Site as random Effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.67</p_value>
            <method>Log Rank</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Compliant Participants With Episode of Self-directed Violence (Per Protocol Analyses)</title>
        <description>Compliance is defined as taking 80% or more of study medication over the entire clinical trial.&#xD;
Episode of self-directed violence is defined as: First Repeated Episode of Suicide Related Event, Including Suicide Attempts, Interrupted Attempts, Hospitalization to Prevent Suicide and death.</description>
        <time_frame>1 year</time_frame>
        <population>Analysis performed for a subset of participants:&#xD;
88 of 519 subjects took 80% or more of their study medication (46 on lithium, 42 on placebo) and were considered substantially compliant. Twenty of these subjects had primary outcomes (8 on placebo, 12 on lithium).</population>
        <group_list>
          <group group_id="O1">
            <title>Lithium (Compliance Per Protocol)</title>
            <description>compliance with study medication, defined as taking 80% or more of their study medication</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Compliance Per Protocol)</title>
            <description>compliance with study medication, defined as taking 80% or more of their study medication</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Compliant Participants With Episode of Self-directed Violence (Per Protocol Analyses)</title>
          <description>Compliance is defined as taking 80% or more of study medication over the entire clinical trial.&#xD;
Episode of self-directed violence is defined as: First Repeated Episode of Suicide Related Event, Including Suicide Attempts, Interrupted Attempts, Hospitalization to Prevent Suicide and death.</description>
          <population>Analysis performed for a subset of participants:&#xD;
88 of 519 subjects took 80% or more of their study medication (46 on lithium, 42 on placebo) and were considered substantially compliant. Twenty of these subjects had primary outcomes (8 on placebo, 12 on lithium).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.37</p_value>
            <method>Log Rank</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>3.64</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Subtypes of Suicidal Self-directed Violence for All Recurring Events</title>
        <description>Subtypes of suicidal self-directed violence:&#xD;
Self-directed violence;&#xD;
Interrupted self-directed violence;&#xD;
Hospitalization to prevent suicide;&#xD;
Death from suicide - there were too few deaths in the study, making data insufficient to perform analysis.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lithium</title>
            <description>Lithium in the form of extended release lithium carbonate. Subjects will be started on 600 mg/day (300mg bid) until steady state at target plasma levels between 0.6 and 0.8 meq/liter is achieved. The lowest dose will be 300 mg/day. Lithium will be prescribed for the duration of follow-up (1 year).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets will be given to the subjects for the duration of follow-up (1 year). Dose adjustments will mimic the intervention arm of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Subtypes of Suicidal Self-directed Violence for All Recurring Events</title>
          <description>Subtypes of suicidal self-directed violence:&#xD;
Self-directed violence;&#xD;
Interrupted self-directed violence;&#xD;
Hospitalization to prevent suicide;&#xD;
Death from suicide - there were too few deaths in the study, making data insufficient to perform analysis.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Suicidal self-directed violence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interrupted suicidal self-directed violence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalization to prevent suicide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death from suicide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Model 5: Non-fatal self-directed violence subgroup</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.77</p_value>
            <method>Log Rank</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>2.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Model 6: Interrupted self-directed violence subgroup</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>Log Rank</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>3.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Model 7: Hospitalization to prevent suicide</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.71</p_value>
            <method>Log Rank</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>1.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data collected over 395 days from randomization</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lithium</title>
          <description>Lithium in the form of extended release lithium carbonate. Subjects will be started on 600 mg/day (300mg bid) until steady state at target plasma levels between 0.6 and 0.8 meq/liter is achieved. The lowest dose will be 300 mg/day. Lithium will be prescribed for the duration of follow-up (1 year).</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo tablets will be given to the subjects for the duration of follow-up (1 year). Dose adjustments will mimic the intervention arm of the study</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Bundle branch block right</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Mesenteric panniculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Serositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Unevaluable event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Product administration error</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Rectal injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Scrotal haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Antipsychotic drug level increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Arachnoid cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Adjustment disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Adjustment disorder with depressed mood</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="255"/>
                <counts group_id="E2" events="22" subjects_affected="10" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Bipolar I disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Bipolar II disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Borderline personality disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="255"/>
                <counts group_id="E2" events="12" subjects_affected="7" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Drug use disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Hallucinations, mixed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Homicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Intentional self-injury</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="255"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Narcissistic personality disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Post-traumatic stress disorder</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="255"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Schizoaffective disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Substance use disorder</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="255"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Substance-induced mood disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Substance-induced psychotic disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="255"/>
                <counts group_id="E2" events="24" subjects_affected="18" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="255"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Suicide threat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Violence-related symptom</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Bereavement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Alcohol detoxification</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Alcohol rehabilitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker insertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Carpal tunnel decompression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Hernia hiatus repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Leg amputation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Mass excision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Nasal septal operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Penile prosthesis insertion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Prostatectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Transurethral prostatectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Wrist surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="193" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="166" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="70" subjects_affected="58" subjects_at_risk="255"/>
                <counts group_id="E2" events="50" subjects_affected="41" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="255"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="48" subjects_affected="40" subjects_at_risk="255"/>
                <counts group_id="E2" events="30" subjects_affected="26" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="255"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="24" subjects_affected="23" subjects_at_risk="255"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="33" subjects_affected="28" subjects_at_risk="255"/>
                <counts group_id="E2" events="24" subjects_affected="23" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="255"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" events="41" subjects_affected="34" subjects_at_risk="255"/>
                <counts group_id="E2" events="32" subjects_affected="22" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="255"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Weight fluctuation</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="255"/>
                <counts group_id="E2" events="22" subjects_affected="21" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="26" subjects_affected="23" subjects_at_risk="255"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="32" subjects_affected="30" subjects_at_risk="255"/>
                <counts group_id="E2" events="35" subjects_affected="33" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="255"/>
                <counts group_id="E2" events="35" subjects_affected="30" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="72" subjects_affected="61" subjects_at_risk="255"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="25" subjects_affected="22" subjects_at_risk="255"/>
                <counts group_id="E2" events="23" subjects_affected="21" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ryan E. Ferguson, ScD, MPH, Director</name_or_title>
      <organization>Boston CSP Coordinating Center</organization>
      <phone>1-857-364-4201</phone>
      <email>Ryan.Ferguson@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

